Loading company…
OxSyns Biotech develops continuous, multi-enzyme systems to produce high-value small molecules.
Founded in 2022, OxSyns Biotech develops bio-electrochemical technologies and systems for producing high-value small molecules. Its coenzyme products are intended for supplements, in vitro diagnostic reagents and cosmetics. The company is based in Shenzhen, China, with R&D centers in Shenzhen and Beijing and a pilot platform in Shanghai. In January 2026, it closed venture funding from ZJVC Venture Capital and Fong Capital Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in